spacer CALDAR Internal Web Site Login
 
             
   
 
 
 

Current Cross-Project Analyses


Long-term Drug Use and Cessation
Led by Yih-Ing Hser, Ph.D.

Objective:  Map the drug use trajectories of users whose primary drug type is heroin, cocaine, or methamphetamine.

Research Questions:

  1. What are the temporal and dynamic trajectories of drug use and how can these trajectories be described?  Are these trajectories similar or dissimilar for different drugs?
  2. How are user characteristics and service system exposure related to drug use trajectories, with a particular focus on stable long-term cessation?
  3. How do these trajectories and relationships compare across drug types?

Drug Treatment Effects over Time
Led by Yih-Ing Hser, Ph.D.

Objective:  Investigate the relationships of multiple treatment episodes to eventual drug use cessation.

Research Questions:

  1. What effects are observable across multiple episodes and different levels of care?  Are rates of relapse reduced, and the rates of transition to eventual cessation over time increased, by each additional treatment episode?
  2. What user and service system characteristics are related to rates of eventual cessation?
  3. Do rates of crime desistance change in parallel with rates of drug cessation?

Drug Use Interplay with Criminal Justice
Led by Michael Prendergast, Ph.D.

Objective:  Compare drug use trajectories from first-time clients who entered treatment under criminal justice system (CJS) coercion and matched cohorts of first-time non-CJS clients.

Research Questions:

  1. For clients in CJS treatment and clients in community treatment, what are the respective temporal and dynamic trajectories of drug use (e.g., onset, acceleration, regular use, cessation, and relapse), and how can these trajectories be described (e.g., rates of acceleration and timing and level of inflection points) before and after the initial treatment?
  2. For clients in CJS treatment and clients in community treatment, how is service system exposure (e.g., drug treatment, CJS involvement, and participation in self-help) related to drug use trajectories, with a particular focus on stable long-term cessation?
  3. For clients in CJS treatment and clients in community treatment, how do their drug use trajectories and the impact of service system exposure compare across primary methamphetamine, cocaine/crack, and heroin users?

Drug Users with Mental Health Disorders
Led by Christine Grella, Ph.D.

Objective:  Better understand the long-term course of drug use and optimal patterns of treatment utilization among drug users with co-occurring mental health disorders.

Research Questions:

  1. What are the temporal and dynamic trajectories of drug use and of treatment exposure for individuals with and without co-occurring mental disorders?
  2. What patterns of treatment exposure and service mix are associated with deceleration and cessation of use among individuals with co-occurring drug use and mental disorders?
  3. What are dynamic trajectories of drug use and service system utilization among individuals with different combinations of substance use and mental disorders? 

Substance Use, Mental Health, and HIV Risk Behaviors
Led by Debra Murphy, Ph.D.

Objective:  Investigate trajectories of drug use and interactions with drug treatment and co-occurring mental disorders to address whether these factors impact HIV risk behaviors.

Research Questions:

  1. Do individuals who have more frequent drug treatment exposure, longer cumulative treatment duration, and shorter intervals between treatment exposures, exhibit lower rates of HIV risk behaviors over time (i.e., effects of cumulative treatment)?
  2. Do individuals with co-occurring mental disorders, who in addition to drug treatment are engaged in mental health treatment, exhibit lower HIV risk behaviors than individuals with co-occurring mental disorders who are only engaged in drug treatment?
  3. Do individuals with co-occurring disorders who show remission of psychiatric symptoms following participation in drug treatment have lower rates of HIV risk behaviors compared to those without symptom remission? 

(Top of Page)

 



[ Home | About Us | Publications | Training & Presentations | Methods/Stats | Analyses | Regulatory | Calendar | Links | Contact Us ]

Integrated Substance Abuse Programs National Institute on Drug AbuseNational Institutes of HealthUCLA
Grant No. P30 DA016383
CALDAR Internal Web Site Login